404
The page you requested doesn't exist
We could not locate the page: /p/may-1st-biotech-pharma-updates
Try one of the featured posts or search the archive below.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | March 11 - 12, 2025
Insilico Medicine $110M Series E, Ono pays Ionis $280M upfront + biobucks for rare blood disease drug, Harbour BioMed launches a newco focused for bispecifics in obesity (with muscle preservation), Seikagaku's FDA CRL for SI-6603 due to manufacturing concerns, Oklahoma confirms first two measles cases linked to Texas-New Mexico outbreak + 21 more stories
Biotech & Pharma Updates | March 10 - 11, 2025
Zealand finds an obesity partner in Roche, 2seventy and it's CAR-T asset scooped up by BMS, Merck & Co. opens a $1B vaccine plant in North Carolina, Illumina earnings bleed at China import ban cuts deep, Roche absorbs gene therapy innovator Spark Therapeutics with $2.4B impairment charge + 25 more stories
Biotech & Pharma Updates | March 9 - 10, 2025
Novo Nordisk's CagriSema Ph3 disappoints investors, Flagship launches AI start-up chasing "scientific superintelligence", Beam Therapeutics notches a Ph1/2 gene-editing win, J&J & Genmab end next-gen anti-CD38 antibody development partnership + 23 more stories
Biotech & Pharma Updates | March 6 - 9, 2025
GLP-1 compounding pharmacies handed another L, Novartis' BTK inhibitor remibrutinib improves sleep in chronic spontaneous urticaria Ph3, Roche launches AI-focused drug development Innovation Center at Harvard in Boston, Molecular Partners & Novartis end three-year radiopharmaceutical drug development partnership, NIH patent filings and licensing applications came to a screeching halt 5 weeks ago and haven't budged since + 29 more stories
Biotech & Pharma Updates | March 5 - 6, 2025
UK's NICE rejects Biogen/Eisai's Leqembi and Eli Lilly's Kisunla for Alzheimer's disease, Neurotech nabs FDA approval for encapsulated cell therapy for macular telangiectasia type 2, Frazier Life Sciences raising new venture fund (XII), federal court approves $700M settlement from various drug companies to 1,000+ hospitals over opioid misconduct allegations, Novo Nordisk to investigate potential of GLP-1 drugs in treating addiction + 29 more stories
Biotech & Pharma Updates | March 4 - 5, 2025
Eli Lilly opens web portal to accept applications for potential US sites as part of $27B investments, Jazz Pharma acquires Chimerix for $935M to gain promising rare brain tumor therapy, Novo Nordisk drops Wegovy's price by 23% to $499 monthly for uninsured patients, BioNTech's mRNA malaria vaccine slapped with FDA clinical hold, CDC boots hit the ground in Texas to assist with growing measles outbreak + 33 more stories
Biotech & Pharma Updates | March 3 - 4, 2025
Illumina sequencers hit with Chinese import ban, Sofinnova Partners raises a €1.2B ($1.3B) healthcare VC fund, BeiGene's PD-1 inhibitor Tevimbra lands another FDA-approved label in first-line esophageal squamous cell carcinoma, Evotec nabs $20M payment as part of neuroscience collab with BMS, DOGE cuts leases for 30 FDA facilities across 23 states + 29 more stories
Biotech & Pharma Updates | March 2 - 3, 2025
AbbVie finally joins the obesity foray (paying Gubra $350M upfront), Novo Nordisk & Gensaic partner to development cardiometabolic therapies using AI-enabled FORGE technology, Callio Therapeutics launches with a $187M Series A and multi-payload ADC aspirations to fight cancer, Lexicon pushes ahead with pilavapadin Ph3 despite failing in Ph2b, top HHS spokesperson abrupt resignation after alleged clashes with RFK Jr. + 28 more stories
Biotech & Pharma Updates | February 27 - March 2, 2025
Eli Lilly signs molecular glue discovery partnership with Magnet Biomedicine, Eisai out-licences FGFR2-targeting tasurgratinib Greater China rights to SciClone, Merck & Co. offered $30M facility build grant by Delaware government, BMS cuts 223 more staff in New Jersey as part of cost-cutting drive, Infectious disease experts plan independent vaccine advisory group pre-empting “eroding” of said committees by RFK Jr. + 26 more stories
Biotech & Pharma Updates | February 26 - 27, 2025
Vertex Pharmaceuticals & Verve Therapeutics end liver disease gene editing collab, BeiGene's BTK inhibitor surpasses AstraZeneca's BTK inhibitor in quarterly sales, Medigene & EpimAb Biotherapeutics co-developing TCR-guided T cell engagers for solid tumors, big pharma players (Eli Lilly, Bristol Myers Squibb, Sanofi and Roche) defy Trump administration’s DEI stance by affirming commitment to diverse clinical trials, Regeneron abandons accelerated approval ambitions for bispecific odronextamab in B cell lymphoma + 31 more stories
Biotech & Pharma Updates | February 25 - 26, 2025
Eli Lilly commits a whopping $27B to build four new US production facilities, Eikon Therapeutics lands a $350.7M Series D to advance engineering + molecular biology driven drug discovery, HBM Alpha Therapeutics licenses CRH antibody therapy to undisclosed partner for up to $395M, AstraZeneca touts positive Ph3 data for camizestrant (estrogen receptor degrader) in certain forms of breast cancer, Idorsia hits dire funding straits as global rights sale of hypertension drug Tryvio falls through + 24 more stories
Biotech & Pharma Updates | February 24 - 25, 2025
Eli Lilly reduces Zepbound vial prices, Regeneron's genetic hearing loss gene therapy improves hearing in 12 pediatric patients, Castle Creek Biosciences $75M royalty financing from Ligand Pharmaceuticals, Takeda & BridGene Biosciences sign $770M small molecule drug discovery/design partnership using IMTAC platform to discovery/design partnership, J&J sues Samsung Bioepis over alleged unlawful Stelara biosimilar sublicensing agreement + 34 more stories